Inventiva S.A. (IVEVF) Research

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other diseases. Its leading drug candidate, Lanifibranor, has successfully completed Phase IIb clinical trials for NASH treatment. The company is also advancing Odiparcil, which has concluded Phase IIa clinical investigation for addressing MPS VI subtype disease. Furthermore, Inventiva maintains a pipeline of earlier-stage programs targeting oncology and other therapeutic areas. The firm has established strategic collaborations, including one with AbbVie for autoimmune diseases and another with Boehringer Ingelheim International GmbH to develop novel treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is headquartered in Daix, France.

Market snapshot

Symbol
IVEVF
Price
$3.59
Day change
0.00%
Market cap
$426.2M
P/E ratio
-5.51x
52-week range
2.28-5.75
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months

Peer companies

  • Adcock Ingram Holdings Limited (AIHLF)
  • AnGes, Inc. (AMGXF)
  • Columbia Care Inc. (CCHWF)
  • Opthea Limited (CKDXF)
  • Claritas Pharmaceuticals, Inc. (CLAZF)
  • EBR Systems, Inc. (EBRCZ)
  • Kindstar Globalgene Technology, Inc. (KDGTF)
  • Oxurion N.V. (TBGNF)

Open Inventiva S.A. (IVEVF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.